DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for hypertrophic cardiomyopathy 14 — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHypertrophic cardiomyopathy 14 maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hypertrophic cardiomyopathy 14 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
LIM domain binding 3 (LDB3) — LDB3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gludrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4YDP · 1.4 Å · ligand GLUTAMIC ACID (GLU). Experimental structure, not a prediction.
What the evidence adds up to
A 1986 pathology review of hypertrophic cardiomyopathy (HCM) describes the disease at the tissue level but offers no treatment data. By 1996, a review of medical therapy for symptomatic HCM patients states plainly that no therapies have been proven to improve prognosis and that few randomised trials of symptomatic treatment exist. The major drugs available at that time were beta-blockers, calcium antagonists and disopyramide; the paper presents a step-by-step management plan within these acknowledged limitations. No concrete survival or response rates are given in any of these abstracts.
The 2024 guidelines note that scientific knowledge of HCM has improved significantly, including a better understanding of pathogenesis, advances in imaging, more common genetic analysis, and better characterisation of natural history. The guidelines mention the development of new medications addressing molecular mechanisms linked to the pathophysiology. However, the abstract does not name any specific drug, report any numerical outcomes, or claim that any new therapy has been proven to improve prognosis in a randomised trial.
What is still missing are large, randomised controlled trials that demonstrate a survival benefit or a reduction in hospitalisations for any drug in HCM. The 1996 review explicitly states that such trials are lacking. The 2024 guidelines do not fill that gap with data in the abstract. Patient stratification by genotype or phenotype remains incomplete, and funding for definitive trials of molecularly targeted therapies has not been shown to have produced results that change the 1996 conclusion about prognosis.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Postgraduate Medical Journal · 1986 · 175 citations · open access
Pathology of hypertrophic cardiomyopathy
AbstractJournal Article Pathology of hypertrophic cardiomyopathy Get access E G J Olsen E G J Olsen National Heart Hospital, London W1M 8BA, U.K. Correspondence: E.G.J. Olsen, M.D., F.R.C.Path., F.A.C.C. Search for other works by this author on: Oxford Academic Google Scholar Postgraduate Medical Journal, Volume 62, Issue 728, June 1986, Pages 575–576, https://doi.org/10.1136/pgmj.62.728.575 Published: 01 June 1986
Arquivos Brasileiros de Cardiologia · 2024 · 24 citations · open access
Guidelines on the Diagnosis and Treatment of Hypertrophic Cardiomyopathy - 2024
Abstract1. Introduction Scientific knowledge of hypertrophic cardiomyopathy (HCM) has significantly improved in the past decades. A better understanding of its pathogenesis, significant advances in the use of imaging methods, and the more common application of genetic analysis, in addition to a better characterization of the natural history of this myocardial disease, have profoundly reformulated its clinical and prognostic significance. Conversely, these processes were accompanied by the development of new medications addressing molecular mechanisms intrinsically linked to the pathophysiology and pathogenesis [...]
Journal of Clinical Pharmacy and Therapeutics · 2019 · 14 citations
A rare case of a gabapentin‐induced cardiomyopathy
AbstractWHAT IS KNOWN AND OBJECTIVE: Gabapentin, a γ-aminobutyric acid derivative, is used for the treatment of partial onset seizures, postherpetic neuralgia, diabetic neuropathy and a host of other neurological disorders. CASE DESCRIPTION: A 44-year-old woman with spinal stenosis was prescribed gabapentin for pain. Two months after initiating therapy, she was diagnosed with a new-onset non-ischaemic cardiomyopathy with an ejection fraction of 36% measured on a transthoracic echocardiogram. WHAT IS NEW AND CONCLUSION: A patient with suspected gabapentin-induced cardiomyopathy is reported. However, to date, gabapentin therapy has not been associated with risk of the developing a cardiomyopathy.
Medical Therapy for Symptomatic Patients with Hypertrophic Cardiomyopathy
AbstractHypertrophic cardiomyopathy is a relatively uncommon myocardial disease with a heterogeneous presentation and complex pathophysiology. The condition is often asymptomatic; when symptoms are present, however, they are usually multiple, and each has several potential mechanisms. No therapies have been proven to improve prognosis, and there are few randomized trials of symptomatic treatment. Within these limitations, an approach to assessing the symptomatic patient is presented. The major drugs available for symptomatic therapy, namely beta-blockers, calcium antagonists and disopyramide, are reviewed. An overall management plan and a step-by-step strategy for the treatment of the symptomatic patient are presented.
Journal of Clinical and Nursing Research · 2025 · 0 citations · open access
Progress in Interventional and Surgical Treatment of Obstructive Hypertrophic Cardiomyopathy
AbstractTo improve the treatment effect of obstructive hypertrophic cardiomyopathy, this article focuses on the treatment of obstructive hypertrophic cardiomyopathy and conducts a comprehensive analysis of the disease. It highlights the limitations of traditional treatment methods and elaborates on interventional and surgical treatments. Additionally, this article compares the indications, risks, treatment effects, and costs of the two different treatment methods, providing a reference for doctors and patients in selecting clinical treatment plans.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
